Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

NVO Relative to the S&P 500

NVO Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Novo Nordisk A S (NYSE:NVO) seasonal charts above shows that a Buy Date of November 24 and a Sell Date of March 4 has resulted in a geometric average return of 7.95% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 18 of those periods. This is an excellent rate of success and the return outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 1.59% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsv rd, Denmark.

To download NVO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: NVO